PL2621513T3 - Ekspresja receptora eph w nowotworowych komórkach macierzystych - Google Patents

Ekspresja receptora eph w nowotworowych komórkach macierzystych

Info

Publication number
PL2621513T3
PL2621513T3 PL11778540T PL11778540T PL2621513T3 PL 2621513 T3 PL2621513 T3 PL 2621513T3 PL 11778540 T PL11778540 T PL 11778540T PL 11778540 T PL11778540 T PL 11778540T PL 2621513 T3 PL2621513 T3 PL 2621513T3
Authority
PL
Poland
Prior art keywords
stem cells
receptor expression
tumor stem
eph receptor
eph
Prior art date
Application number
PL11778540T
Other languages
English (en)
Polish (pl)
Inventor
Angelo Luigi Vescovi
Elena Binda
Original Assignee
Stemgen S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S.P.A. filed Critical Stemgen S.P.A.
Publication of PL2621513T3 publication Critical patent/PL2621513T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL11778540T 2010-10-01 2011-09-30 Ekspresja receptora eph w nowotworowych komórkach macierzystych PL2621513T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
EP11778540.2A EP2621513B1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Publications (1)

Publication Number Publication Date
PL2621513T3 true PL2621513T3 (pl) 2017-06-30

Family

ID=43856109

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11778540T PL2621513T3 (pl) 2010-10-01 2011-09-30 Ekspresja receptora eph w nowotworowych komórkach macierzystych

Country Status (11)

Country Link
US (1) US9078857B2 (enExample)
EP (2) EP2446895A1 (enExample)
JP (4) JP2013540117A (enExample)
KR (2) KR20130095286A (enExample)
AU (1) AU2011310109B2 (enExample)
CA (1) CA2813101C (enExample)
DK (1) DK2621513T3 (enExample)
ES (1) ES2616444T3 (enExample)
NZ (1) NZ609594A (enExample)
PL (1) PL2621513T3 (enExample)
WO (1) WO2012042021A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
SMT202100146T1 (it) 2014-04-30 2021-05-07 Pfizer Coniugati di anticorpo anti-ptk7-farmaco
ES2796973T3 (es) 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
US10783439B2 (en) * 2015-05-08 2020-09-22 FlowJo, LLC Plugin interface and framework for integrating a remote server with sample data analysis software
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US20240226175A1 (en) * 2020-03-31 2024-07-11 Keio University Therapeutic agent using genome-edited pluripotent stem cell
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060130038A (ko) * 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 EphA2 백신
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗epha2抗体

Also Published As

Publication number Publication date
AU2011310109A1 (en) 2013-05-02
DK2621513T3 (en) 2017-03-06
JP2018048151A (ja) 2018-03-29
WO2012042021A1 (en) 2012-04-05
EP2621513B1 (en) 2016-12-28
JP6523910B2 (ja) 2019-06-05
CA2813101C (en) 2018-10-30
US9078857B2 (en) 2015-07-14
JP2020037579A (ja) 2020-03-12
JP6618968B2 (ja) 2019-12-11
KR20130095286A (ko) 2013-08-27
KR101719966B1 (ko) 2017-03-24
JP2016094391A (ja) 2016-05-26
AU2011310109B2 (en) 2014-11-20
JP2013540117A (ja) 2013-10-31
US20120083454A1 (en) 2012-04-05
ES2616444T3 (es) 2017-06-13
NZ609594A (en) 2015-01-30
KR20160027106A (ko) 2016-03-09
EP2621513A1 (en) 2013-08-07
CA2813101A1 (en) 2012-04-05
EP2446895A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
IL250234B (en) Creating blood vessels using placental stem cells
GB201013639D0 (en) Cell selection
PT2785834T (pt) Composição de células estaminais melhorada
IL216624A0 (en) Fucosylation-deficient cells
GB201000375D0 (en) T Cell clonotypes
ZA201300621B (en) T cell receptors
EP2724644A4 (en) CUSHION CELL AND CUSHION BODY USING THE SAME
EP2601290A4 (en) SOMATIC STEM CELLS
GB201017421D0 (en) Cell
EP2760996A4 (en) SOMATIC STEM CELLS
IL237228B (en) Stem cells that improve healing
GB201001156D0 (en) Photovoltaic cell
GB2484455B (en) Photovoltaic cells
GB201014823D0 (en) Solar cell
GB201012052D0 (en) Glyco-engineering in lower eukaryotic cells
GB201112476D0 (en) Glyco-engineering in lower eukaryotic cells
GB201020580D0 (en) Cells
GB201019304D0 (en) Cells
EP2598166A4 (en) CELLS WITHOUT CMH
GB201019108D0 (en) Cell
GB0918471D0 (en) Stem cells
GB201010803D0 (en) Photovoltaic cells
GB201021372D0 (en) CD24 cancer stem cell
TWM390096U (en) Style chair
PL2593113T3 (pl) Terapia komórkowa